Nothing Special   »   [go: up one dir, main page]

Maschauer et al., 2014 - Google Patents

In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study

Maschauer et al., 2014

View HTML
Document ID
3809547197299948878
Author
Maschauer S
Ruckdeschel T
Tripal P
Haubner R
Einsiedel J
Hübner H
Gmeiner P
Kuwert T
Prante O
Publication year
Publication venue
Pharmaceuticals

External Links

Snippet

The neurotensin receptor (NTS1) has emerged as an interesting target for molecular imaging and radiotherapy of NTS-positive tumors due to the overexpression in a range of tumors. The aim of this study was to develop a 177Lu-labeled NTS1 radioligand, its …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Hennrich et al. [68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging
Hennrich et al. Lutathera®: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy
Varasteh et al. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin
Mitran et al. Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer
Kaloudi et al. NeoBOMB1, a GRPR-antagonist for breast cancer theragnostics: First results of a preclinical study with [67Ga] NeoBOMB1 in T-47D cells and tumor-bearing mice
Maschauer et al. In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study
Hu et al. Radiosynthesis and preclinical evaluation of bispecific PSMA/FAP heterodimers for tumor imaging
Abouzayed et al. Synthesis and preclinical evaluation of radio-iodinated GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer
Dahlsson Leitao et al. Molecular design of HER3-targeting affibody molecules: Influence of chelator and presence of HEHEHE-tag on biodistribution of 68Ga-labeled tracers
Bendre et al. Evaluation of Met-Val-Lys as a renal brush border enzyme-cleavable linker to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides and peptidomimetics
Nock et al. [99mTc] Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes
Wharton et al. Preclinical Evaluation of [155/161Tb] Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours
Maschauer et al. Theranostic value of multimers: lessons learned from trimerization of neurotensin receptor ligands and other targeting vectors
Summer et al. Pretargeted imaging with Gallium-68—improving the binding capability by increasing the number of tetrazine motifs
Klingler et al. Cholecystokinin-2 receptor targeting with novel c-terminally stabilized HYNIC-Minigastrin analogs radiolabeled with technetium-99m
Hörmann et al. Radiopharmaceutical formulation and preclinical testing of 68Ga-labeled DOTA-MGS5 for the regulatory approval of a first exploratory clinical trial
Lundmark et al. Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation
Lo et al. Molecular imaging and preclinical studies of radiolabeled long-term RGD peptides in U-87 MG tumor-bearing mice
Fani et al. Selection of the first 99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation—Preclinical assessment of two optimized candidates
Wang et al. 68Ga-Labeled [Thz14] Bombesin (7–14) analogs: Promising GRPR-targeting agonist PET tracers with low pancreas uptake
Trencsényi et al. Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis
Hörmann et al. Effect of N-terminal peptide modifications on in vitro and in vivo properties of 177Lu-labeled peptide analogs targeting CCK2R
Lymperis et al. Comparing Gly11/dAla11-replacement vs. the in-situ neprilysin-inhibition approach on the tumor-targeting efficacy of the 111In-SB3/111In-SB4 radiotracer pair
Baun et al. Preclinical evaluation of the copper-64 labeled GRPR-antagonist RM26 in comparison with the cobalt-55 labeled counterpart for PET-imaging of prostate cancer
Gaonkar et al. SPECT imaging of SST2-expressing tumors with 99mTc-based somatostatin receptor antagonists: The role of tetraamine, HYNIC, and spacers